Daclizumab use in patients with pediatric multiple sclerosis

Mark P. Gorman, Jan-Mendelt Tillema, Annika M. Ciliax, Charles R G Guttmann, Tanuja Chitnis

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Background: Daclizumab, a humanized monoclonal antibody specific for the interleukin 2 receptor α chain, reduces clinical and magnetic resonance imaging disease activity in patients with adult-onset multiple sclerosis (MS) as monotherapy or add-on therapy with interferon. Objective: To report the use of daclizumab in pediatric-onset MS. Design: Case series. Setting: Two comprehensive pediatric MS centers. Patients: Seven patients with pediatric-onset MS with clinical and magnetic resonance imaging disease activity despite first-line disease-modifying therapy. Intervention: Intravenous daclizumab, 1 mg/kg monthly. Main Outcome Measures: Annualized relapse rates, Expanded Disability Status Scale scores, contrast-enhancing lesions, and adverse effects. Results: Treatment with daclizumab, primarily combined with interferon, was associated with reductions in annualized relapse rates and contrast-enhancing lesions and with reduction or stabilization of Expanded Disability Status Scale scores in each patient. However, 4 patients had relapses and new contrast-enhancing lesions during daclizumab treatment. No significant adverse effects occurred. Conclusion: Daclizumab may be a safe and at least partially effective treatment option for patients with pediatric-onset MS with disease activity despite first-line disease-modifying therapy.

Original languageEnglish (US)
Pages (from-to)78-81
Number of pages4
JournalArchives of Neurology
Volume69
Issue number1
DOIs
StatePublished - Jan 2012
Externally publishedYes

Fingerprint

Multiple Sclerosis
Pediatrics
Recurrence
Interferons
Therapeutics
Magnetic Resonance Imaging
Antibodies, Monoclonal, Humanized
Interleukin-2 Receptors
daclizumab
Outcome Assessment (Health Care)
Onset
Relapse
Lesion
Therapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Arts and Humanities (miscellaneous)

Cite this

Daclizumab use in patients with pediatric multiple sclerosis. / Gorman, Mark P.; Tillema, Jan-Mendelt; Ciliax, Annika M.; Guttmann, Charles R G; Chitnis, Tanuja.

In: Archives of Neurology, Vol. 69, No. 1, 01.2012, p. 78-81.

Research output: Contribution to journalArticle

Gorman, Mark P. ; Tillema, Jan-Mendelt ; Ciliax, Annika M. ; Guttmann, Charles R G ; Chitnis, Tanuja. / Daclizumab use in patients with pediatric multiple sclerosis. In: Archives of Neurology. 2012 ; Vol. 69, No. 1. pp. 78-81.
@article{31bb40f3271544ec83d95e294f502786,
title = "Daclizumab use in patients with pediatric multiple sclerosis",
abstract = "Background: Daclizumab, a humanized monoclonal antibody specific for the interleukin 2 receptor α chain, reduces clinical and magnetic resonance imaging disease activity in patients with adult-onset multiple sclerosis (MS) as monotherapy or add-on therapy with interferon. Objective: To report the use of daclizumab in pediatric-onset MS. Design: Case series. Setting: Two comprehensive pediatric MS centers. Patients: Seven patients with pediatric-onset MS with clinical and magnetic resonance imaging disease activity despite first-line disease-modifying therapy. Intervention: Intravenous daclizumab, 1 mg/kg monthly. Main Outcome Measures: Annualized relapse rates, Expanded Disability Status Scale scores, contrast-enhancing lesions, and adverse effects. Results: Treatment with daclizumab, primarily combined with interferon, was associated with reductions in annualized relapse rates and contrast-enhancing lesions and with reduction or stabilization of Expanded Disability Status Scale scores in each patient. However, 4 patients had relapses and new contrast-enhancing lesions during daclizumab treatment. No significant adverse effects occurred. Conclusion: Daclizumab may be a safe and at least partially effective treatment option for patients with pediatric-onset MS with disease activity despite first-line disease-modifying therapy.",
author = "Gorman, {Mark P.} and Jan-Mendelt Tillema and Ciliax, {Annika M.} and Guttmann, {Charles R G} and Tanuja Chitnis",
year = "2012",
month = "1",
doi = "10.1001/archneurol.2011.581",
language = "English (US)",
volume = "69",
pages = "78--81",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - Daclizumab use in patients with pediatric multiple sclerosis

AU - Gorman, Mark P.

AU - Tillema, Jan-Mendelt

AU - Ciliax, Annika M.

AU - Guttmann, Charles R G

AU - Chitnis, Tanuja

PY - 2012/1

Y1 - 2012/1

N2 - Background: Daclizumab, a humanized monoclonal antibody specific for the interleukin 2 receptor α chain, reduces clinical and magnetic resonance imaging disease activity in patients with adult-onset multiple sclerosis (MS) as monotherapy or add-on therapy with interferon. Objective: To report the use of daclizumab in pediatric-onset MS. Design: Case series. Setting: Two comprehensive pediatric MS centers. Patients: Seven patients with pediatric-onset MS with clinical and magnetic resonance imaging disease activity despite first-line disease-modifying therapy. Intervention: Intravenous daclizumab, 1 mg/kg monthly. Main Outcome Measures: Annualized relapse rates, Expanded Disability Status Scale scores, contrast-enhancing lesions, and adverse effects. Results: Treatment with daclizumab, primarily combined with interferon, was associated with reductions in annualized relapse rates and contrast-enhancing lesions and with reduction or stabilization of Expanded Disability Status Scale scores in each patient. However, 4 patients had relapses and new contrast-enhancing lesions during daclizumab treatment. No significant adverse effects occurred. Conclusion: Daclizumab may be a safe and at least partially effective treatment option for patients with pediatric-onset MS with disease activity despite first-line disease-modifying therapy.

AB - Background: Daclizumab, a humanized monoclonal antibody specific for the interleukin 2 receptor α chain, reduces clinical and magnetic resonance imaging disease activity in patients with adult-onset multiple sclerosis (MS) as monotherapy or add-on therapy with interferon. Objective: To report the use of daclizumab in pediatric-onset MS. Design: Case series. Setting: Two comprehensive pediatric MS centers. Patients: Seven patients with pediatric-onset MS with clinical and magnetic resonance imaging disease activity despite first-line disease-modifying therapy. Intervention: Intravenous daclizumab, 1 mg/kg monthly. Main Outcome Measures: Annualized relapse rates, Expanded Disability Status Scale scores, contrast-enhancing lesions, and adverse effects. Results: Treatment with daclizumab, primarily combined with interferon, was associated with reductions in annualized relapse rates and contrast-enhancing lesions and with reduction or stabilization of Expanded Disability Status Scale scores in each patient. However, 4 patients had relapses and new contrast-enhancing lesions during daclizumab treatment. No significant adverse effects occurred. Conclusion: Daclizumab may be a safe and at least partially effective treatment option for patients with pediatric-onset MS with disease activity despite first-line disease-modifying therapy.

UR - http://www.scopus.com/inward/record.url?scp=84855574271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855574271&partnerID=8YFLogxK

U2 - 10.1001/archneurol.2011.581

DO - 10.1001/archneurol.2011.581

M3 - Article

VL - 69

SP - 78

EP - 81

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 1

ER -